Search - tctmd.com

Displaying 441 - 460 of 1608

Sort: Relevancy | Date

Long-Awaited BEST-CLI Results Favor Surgery Over Endovascular Therapy in CLTI

News Conference News AHA 2022

Long-Awaited BEST-CLI Results Favor Surgery Over Endovascular Therapy in CLTI

November 07, 2022

PRECISE CT-Based Strategy Allows Clinicians to ‘Do Less’ for Stable Chest Pain

News Conference News AHA 2022

PRECISE CT-Based Strategy Allows Clinicians to ‘Do Less’ for Stable Chest Pain

Yael L. Maxwell

November 06, 2022

EMPA-KIDNEY: Empagliflozin a ‘Win’ for Patients With CKD

News Conference News AHA 2022

EMPA-KIDNEY: Empagliflozin a ‘Win’ for Patients With CKD

November 06, 2022

‘Dramatic’ Reductions in Lp(a) With Olpasiran: OCEAN(a)-DOSE

News Conference News AHA 2022

‘Dramatic’ Reductions in Lp(a) With Olpasiran: OCEAN(a)-DOSE

Michael O'Riordan

November 06, 2022

IRONMAN Misses but Lends Support to IV Iron Repletion in HF

News Conference News AHA 2022

IRONMAN Misses but Lends Support to IV Iron Repletion in HF

November 05, 2022

Pemafibrate Fails to Lower CVD Risk in Patients With High Triglycerides: PROMINENT

News Conference News AHA 2022

Pemafibrate Fails to Lower CVD Risk in Patients With High Triglycerides: PROMINENT

Michael O'Riordan

November 05, 2022

High-Sensitivity Troponin Testing on the Rise in the US, but Still Limited

News Conference News AHA 2022

High-Sensitivity Troponin Testing on the Rise in the US but Still Limited

Michael O'Riordan

November 04, 2022

‘Heartless’ Indifference Drives PAD/CLTI Amputations in Underserved Groups

News Conference News VIVA 2022

‘Heartless’ Indifference Drives PAD/CLTI Amputations in Underserved Groups

November 04, 2022

TRANSCEND: Low-Dose DCB for PAD Still Looking Good at 2 Years

News Conference News VIVA 2022

TRANSCEND: Low-Dose DCB for PAD Still Looking Good at 2 Years

November 03, 2022

Extreme BP-Lowering Harmful After Stroke Thrombectomy: ENCHANTED2/MT

News Daily News

Extreme BP-Lowering Harmful After Stroke Thrombectomy: ENCHANTED2/MT

November 01, 2022

Novel Intervention to Increase GDMT in HF Exploits Noncardiac Admissions

News Conference News AHA 2022

Novel Intervention to Increase GDMT in HF Exploits Noncardiac Admissions

Yael L. Maxwell

November 01, 2022

Stroke Thrombectomy May Work for Large Infarcts in the Late Time Window

News Daily News

Stroke Thrombectomy May Work for Large Infarcts in the Late Time Window

October 20, 2022

Hints of Benefit With Catheter-Directed Thrombolysis in Intermediate/High-Risk PE

News Daily News

Hints of Benefit With Catheter-Directed Thrombolysis in Intermediate/High-Risk PE

October 19, 2022

SPRINT Turns Sluggish: Mortality Benefits Vanish Once Normal Care Resumes

News Daily News

SPRINT Turns Sluggish: Mortality Benefits Vanish Once Normal BP Care Resumes

Michael O'Riordan

October 18, 2022

Off Script: Is the Next Generation ‘Weak’ or Do We Need Higher Standards for Ourselves?

News Opinion Off Script

Is the Next Generation ‘Weak’ or Do We Need Higher Standards for Ourselves?

Ajay Kirtane, MD, SM

October 18, 2022

CAST-HF: Could Myocardial Shockwave During CABG Yield Cardiac Regeneration?

News Conference News EACTS 2022

CAST-HF: Could Myocardial Shockwave During CABG Yield Cardiac Regeneration?

October 12, 2022

COAPT Risk Score Useful in Predicting Outcomes in Functional MR

News Daily News

COAPT Risk Score Useful in Predicting Outcomes in Functional MR

Michael O'Riordan

October 05, 2022

Sky-high Cost of SGLT2i and GLP1 Agonists Deter First-line Use

News Daily News

Sky-high Cost of SGLT2i and GLP1 Agonists Deter First-line Use

October 05, 2022

NSTEMI Patients With CKD: Early Invasive vs Delayed Strategy Similar for Survival

News Daily News

NSTEMI Patients With CKD: Early Invasive vs Delayed Strategy Similar for Survival

October 03, 2022

Concerning or Reassuring? Long After COVID-19, CMR Still Yields Clues

News Daily News

Concerning or Reassuring? Long After COVID-19, CMR Still Yields Clues

Michael O'Riordan

October 03, 2022

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.